- Home
- ARVN vs CRAN Comparison
ARVN vs CRAN Comparison
Compare ARVN & CRAN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ARVN | CRAN |
|---|---|---|
| Founded | 2015 | 2025 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Blank Checks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 516.2M | 472.3M |
| IPO Year | 2018 | N/A |
Fundamental Metrics
Financial Performance| Metric | ARVN | CRAN |
|---|---|---|
| Price | $8.11 | $10.16 |
| Analyst Decision | Buy | |
| Analyst Count | 19 | 0 |
| Target Price | ★ $15.05 | N/A |
| AVG Volume (30 Days) | ★ 685.8K | 124.5K |
| Earning Date | 05-04-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 58.84 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $262,600,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $6.06 | $9.90 |
| 52 Week High | $14.22 | $10.21 |
Technical Indicators
Market Signals| Indicator | ARVN | CRAN |
|---|---|---|
| Relative Strength Index (RSI) | 45.64 | 58.03 |
| Support Level | N/A | $9.97 |
| Resistance Level | $8.90 | N/A |
| Average True Range (ATR) | 0.38 | 0.03 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 18.50 | 54.55 |
Price Performance
Historical ComparisonAbout ARVN Arvinas Inc.
Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.
About CRAN Crane Harbor Acquisition Corp. II Class A Ordinary Shares
Crane Harbor Acquisition Corp II is a blank check company formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities.